Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
History, Applications, Art & Companies
Explore the main themes, entities and connections around Olaratumab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
doxorubicin european 2019 antibody sarcoma trial patients phase drug lilly treatment united states fda lartruvo side effects medical uses infusion
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Olaratumab | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Olaratumab | ATC code | L01FX10 (WHO) | 1.00 | infobox |
| Olaratumab | CAS Number | 1024603-93-7 N | 1.00 | infobox |
| Olaratumab | ChemSpider | None | 1.00 | infobox |
| Olaratumab | DrugBank | DB06043 Y | 1.00 | infobox |
| Olaratumab | Elimination half-life | 11 days | 1.00 | infobox |
| Olaratumab | Formula | C6554H10076N1736O2048S40 | 1.00 | infobox |
| Olaratumab | KEGG | D09939 N | 1.00 | infobox |
| Olaratumab | Legal status | CA: ℞-only | 1.00 | infobox |
| Olaratumab | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Olaratumab | Legal status | US: ℞-only | 1.00 | infobox |
| Olaratumab | License data | US DailyMed: Lartruvo | 1.00 | infobox |
| Olaratumab | Metabolism | Proteolytic enzymes | 1.00 | infobox |
| Olaratumab | Molar mass | 147241.21 g·mol−1 | 1.00 | infobox |
| Olaratumab | Other names | IMC-3G3, LY-3012207 | 1.00 | infobox |
| Olaratumab | Protein binding | None | 1.00 | infobox |
| Olaratumab | Routes of administration | Intravenous infusion | 1.00 | infobox |
| Olaratumab | Source | Human | 1.00 | infobox |
| Olaratumab | Target | PDGF-R α | 1.00 | infobox |
| Olaratumab | Trade names | Lartruvo | 1.00 | infobox |
| Olaratumab | Type | Whole antibody | 1.00 | infobox |
| Olaratumab | UNII | TT6HN20MVF | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.